NCT05351593: An ongoing trial by James Rubenstein
This trial is ongoing. It must report results 5 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05351593 |
|---|---|
| Title | A Phase I/II Study of Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 8, 2022 |
| Completion date | Sept. 30, 2025 |
| Required reporting date | Sept. 30, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |